ObvioGo Integrates with Oracle Life Sciences Clinical One Data Collection

The companies said the move is intended to reduce reliance on multiple third-party systems while supporting operational consistency and scalability across global studies.

ObvioHealth’s ObvioGo platform has been directly integrated with Oracle Health and Life Sciences Clinical One Data Collection, expanding decentralized and hybrid clinical trial capabilities within Oracle’s clinical research portfolio, the companies announced Tuesday.

The integration allows sponsors and contract research organizations (CROs) to deploy participant-facing technologies such as electronic patient-reported outcomes (ePRO), electronic consent (eConsent), and electronic clinical outcome assessments (eCOA) through ObvioGo within Oracle’s unified Clinical One environment.

The companies said the move is intended to reduce reliance on multiple third-party systems while supporting operational consistency and scalability across global studies.

Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, said the integration aligns with Oracle’s focus on connected, enterprise-grade clinical development solutions. “With ObvioGo, we are expanding access to decentralized trial capabilities that integrate seamlessly within Oracle Health and Life Sciences' product portfolio,” she said.

The integrated solution is designed to support decentralized and hybrid study models while maintaining data quality, operational oversight, and regulatory compliance. By embedding ObvioGo into the Clinical One Data Collection platform, organizations can configure and deliver participant-facing trial technologies as part of a broader clinical trial system.

Richard Watkins, chief revenue officer at ObvioHealth, said the integration marks a milestone for the company. “Being integrated and sold as part of Oracle Health and Life Sciences validates ObvioGo as an enterprise-ready participant technology platform designed to operate at a global scale,” he said.

Ivan Jarry, CEO of ObvioHealth, added that the collaboration is aimed at simplifying trial operations while supporting flexible study designs. “This collaboration enables sponsors to simplify trial operations while maintaining the flexibility required to support decentralized and hybrid study designs,” he said.

The companies also noted that Oracle’s broader ecosystem—including Oracle Cloud Infrastructure, Oracle Life Sciences AI Application Suite, and Oracle Fusion Cloud applications—supports interoperability across clinical development, supply chain, and commercial functions.

Stay tuned for more such updates on Digital Health News